预约演示
更新于：2025-07-09
Folic Acid
叶酸
更新于：2025-07-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1947-06-02), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19N7O6 |
InChIKeyOVBPIULPVIDEAO-LBPRGKRZSA-N |
CAS号59-30-3 |
关联
468
项与 叶酸 相关的临床试验NCT07013136
Efficacy and Safety of Folic Acid on Acute Kidney Injury in Adults: A Feasibility Study
CTRI/2025/04/085275
Comparison of once daily vs twice daily therapeutic IFA for change in hemoglobin among school going adolescent girls in rural Haryana: An open-labelled non-inferiority cluster randomised controlled trial - NIL
NCT06015750
An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)
100 项与 叶酸 相关的临床结果
登录后查看更多信息
100 项与 叶酸 相关的转化医学
登录后查看更多信息
100 项与 叶酸 相关的专利（医药）
登录后查看更多信息
68,046
项与 叶酸 相关的文献（医药）2025-12-31Gut Microbes
Cross-feeding-based rational design of a probiotic combination of
Bacterides xylanisolvens
and
Clostridium butyricum
therapy for metabolic diseases
Article
作者: Wang, Tao ; Han, Junjie ; Liu, Chang ; Yang, Lan ; Dai, Huanqin ; Guo, Chun-Jun ; Liu, Shuang-Jiang ; Qiao, Shanshan ; Sun, Jingzu ; Liu, Hongwei ; Du, Mengxuan
The human gut microbiota has gained interest as an environmental factor that contributes to health or disease. The development of next-generation live biotherapeutic products (LBPs) is a promising strategy to modulate the gut microbiota and improve human health. In this study, we identified a novel cross-feeding interaction between Bacteroides xylanisolvens and Clostridium butyricum and developed their combination into a novel LBP for treating metabolic syndrome. Using in-silico analysis and in vitro experiments, we demonstrated that B. xylanisolvens supported the growth and butyrate production of C. butyricum by supplying folate, while C. butyricum reciprocated by providing pABA for folate biosynthesis. Animal gavage experiments showed that the two-strain combination LBP exhibited superior therapeutic efficacy against metabolic disorders in high-fat diet-induced obese (DIO) mice compared to either single-strain treatment. Further omics-based analyses revealed that the single-strain treatments exhibited distinct taxonomic preferences in modulating the gut microbiota, whereas the combination LBP achieved more balanced modulation to preserve taxonomic diversity to a greater extent, thereby enhancing the stability and resilience of the gut microbiome. Moreover, the two-strain combinations more effectively restored gut microbial functions by reducing disease-associated pathways and opportunistic pathogen abundance. This work demonstrates the development of new LBP therapy for metabolic diseases from cross-feeding microbial pairs which exerted better self-stability and robust efficacy in complex intestinal environments compared to conventional single-strain LBPs.
2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Early gestational diabetes mellitus risk predictor using neural network with NearMiss
Article
作者: Su, Xiaojie ; Huang, Lihong ; Zhao, Min
BACKGROUND:
Gestational diabetes mellitus (GDM) is globally recognized as a significant pregnancy-related condition, contributing to complex complications for both mothers and infants. Traditional glucose tolerance tests lack the ability to identify the risk of GDM in early pregnancy, hindering effective prevention and timely intervention during the initial stages.
OBJECTIVE:
The primary objective of this study is to pinpoint potential risk factors for GDM and develop an early GDM risk prediction model using neural networks to facilitate GDM screening in early pregnancy.
METHODS:
Initially, we employed statistical tests and models, including univariate and multivariate logistic regression, to identify 14 potential risk factors. Subsequently, we applied various resampling techniques alongside a multi-layer perceptron (MLP). Finally, we evaluated and compared the classification performances of the constructed models using various metric indicators.
RESULTS:
As a result, we identified several factors in early pregnancy significantly associated with GDM (p < 0.05), including BMI, age of menarche, age, higher education, folic acid supplementation, family history of diabetes mellitus, HGB, WBC, PLT, Scr, HBsAg, ALT, ALB, and TBIL. Employing the multivariate logistic model as the baseline achieved an accuracy and AUC of 0.777. In comparison, the MLP-based model using NearMiss exhibited strong predictive performance, achieving scores of 0.943 in AUC and 0.884 in accuracy.
CONCLUSIONS:
In this study, we proposed an innovative interpretable early GDM risk prediction model based on MLP. This model is designed to offer assistance in estimating the risk of GDM in early pregnancy, enabling proactive prevention and timely intervention.
2025-12-31Journal of the International Society of Sports Nutrition
Survey of nutritional intake status in college baseball players
Article
作者: Aoyama, Yuka ; Tanaka, Mamoru ; Seguchi, Manato ; Iio, Yoko ; Kozai, Hana ; Mori, Yukihiro ; Ito, Morihiro
BACKGROUND:
Diet is closely related to exercise performance. To improve athletes' performance and manage their condition, it is important to get sufficient energy and various nutrients. Thus, it is necessary that athletes understand their nutritional intake status to improve performance and maintain health. This study aimed to explore the nutritional intake status of college baseball players using the Food Frequency Questionnaire (FFQ). Furthermore, the characteristics of their nutritional intake status with respect to athletic performance were evaluated. The result of this studyprovide an opportunity for many under-developed college athletes with irregular lifestyles to recognize and improve their nutritional problems.
METHODS:
In October 2022, a questionnaire survey of 116 male members of a college baseball club was conducted. Of whom, 100 (94.3%) members responded to the survey and 92 (92.0%) provided valid responses. The survey items included basic characteristics such as college grade and type of living arrangement, and information on living conditions, e.g. whether the participant ate breakfast. Nutritional intake was evaluated using the FFQ. Players were divided into the first (regular players in official games), second (bench players in official games), third (players who may join the second or higher team in the future), and fourth teams (players who do not belong to the first to third teams); these categories were used as a marker of performance level. The Kruskal-Wallis test was used to analyze the association between the performance levels of baseball players and the intake of each nutrient and food group obtained by the FFQ. For items that showed a significant association, inter-group comparison was performed using the Dunn-Bonferroni method.
RESULTS:
Carbohydrate intake was greater in the second team compared with the third and fourth teams; saturated and monounsaturated fatty acid intake was higher in the third team compared with the fourth team. Calcium, zinc, copper, manganese, insoluble dietary fiber, iodine, and molybdenum intake was higher in the second team compared with the fourth team. Intake of grains, sugar, dairy, and total energy was significantly higher in the second team compared with the fourth team. However, the protein intake ratio was significantly lower in the second team compared with the fourth team. Overall, energy deficiency and associated deficiencies in protein, fat, and carbohydrate were observed, in addition to dietary fiber and calcium deficiencies. The intake of several food groups appeared inadequate, such as potatoes, beans, vegetables, fruits, eggs, milk, and fats.
CONCLUSIONS:
The study showed deficiencies in the amount of energy and nutrients such as protein, fat, and carbohydrate in college baseball players. Differences in the intake of carbohydrate, calcium, and insoluble dietary fiber among different performance levels were observed, with significantly higher intake of carbohydrate, calcium, and insoluble dietary fiber in the second team. Implementing organized and strategic remedial measures and athletes' identification of nutritional problems are vital to overcome nutritional and energy deficiencies. This study provides useful information for the development of strategies to support nutritional intake in college baseball players.
100 项与 叶酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨幼红细胞性贫血 | 中国 | 1981-01-01 | |
| 叶酸缺乏 | 日本 | 1950-08-01 | |
| 神经管缺陷 | 美国 | 1947-06-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高同种半胱胺酸血症 | 临床2期 | 中国 | 2025-07-08 | |
| 非鳞状非小细胞肺癌 | 临床2期 | 澳大利亚 | 2008-02-01 | |
| 非鳞状非小细胞肺癌 | 临床2期 | 意大利 | 2008-02-01 | |
| 非鳞状非小细胞肺癌 | 临床2期 | 墨西哥 | 2008-02-01 | |
| 非鳞状非小细胞肺癌 | 临床2期 | 西班牙 | 2008-02-01 | |
| 避孕 | 临床1期 | - | 2005-01-01 | |
| 缺血性卒中 | 临床申请批准 | 中国 | 2024-09-24 | |
| 同型半胱氨酸血症 | 临床申请批准 | 中国 | 2022-11-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Folate supplementation) | 網蓋齋艱遞積網鹽網獵(蓋選鑰選蓋襯窪範壓膚) = 遞餘製築窪鑰繭鬱艱膚 壓顧蓋壓齋壓顧憲蓋夢 (網築齋願鹹築鹽膚廠鏇, -1.74 ~ -0.78) | - | 2024-06-14 | ||
N/A | - | - | High-dose folic acid | 遞鑰窪衊構網鑰醖衊醖(鑰範鬱淵衊獵鹹壓鹽廠): aHR = 0.8 (95% CI, 0.63 ~ 1.02) | 积极 | 2023-09-04 | |
No high-dose folic acid | |||||||
临床2/3期 | 289 | (Ascorbic Acid and Folic Acid) | 壓願淵鏇廠觸齋襯範蓋 = 膚遞衊淵齋憲壓衊獵積 願遞鬱願製憲顧範淵艱 (鹹餘築鏇遞範蓋淵窪鹽, 艱鹹衊繭壓衊艱糧網蓋 ~ 窪壓構鹽簾繭艱構構蓋) 更多 | - | 2022-08-08 | ||
(Hydroxychloroquine and Folic Acid) | 壓願淵鏇廠觸齋襯範蓋 = 鏇鹽衊鏇築顧糧構窪壓 願遞鬱願製憲顧範淵艱 (鹹餘築鏇遞範蓋淵窪鹽, 壓膚構簾衊膚膚獵壓願 ~ 淵齋糧顧糧憲繭襯鬱廠) 更多 | ||||||
N/A | - | Folic acid only | - | - | 2022-06-01 | ||
临床4期 | 152 | gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX) | 淵製壓願遞淵鏇鬱糧簾 = 衊簾選糧鑰醖憲壓製齋 餘鏇淵廠蓋廠繭艱齋網 (網廠鏇蓋鬱獵憲糧壓選, 獵糧選憲觸襯鹽獵築築 ~ 艱網醖壓遞鏇鑰網襯築) 更多 | - | 2022-05-16 | ||
(Pegloticase + Placebo) | 淵製壓願遞淵鏇鬱糧簾 = 醖衊構餘積願選觸夢網 餘鏇淵廠蓋廠繭艱齋網 (網廠鏇蓋鬱獵憲糧壓選, 窪範選艱構鏇膚蓋蓋觸 ~ 艱壓夢積壓艱範餘鑰襯) 更多 | ||||||
临床2期 | 252 | (Placebo) | 艱觸積齋觸淵窪願鹹艱 = 繭網餘壓構願窪鏇觸獵 繭繭網範簾窪廠築廠繭 (繭淵夢繭廠憲構廠鹽衊, 製壓遞衊獵膚襯廠襯積 ~ 夢願遞鏇膚醖獵鹹獵窪) 更多 | - | 2021-12-21 | ||
(Brodalumab 70 mg) | 艱觸積齋觸淵窪願鹹艱 = 積衊夢簾鏇網夢觸構鬱 繭繭網範簾窪廠築廠繭 (繭淵夢繭廠憲構廠鹽衊, 範壓糧鑰鹽製構鹽壓廠 ~ 餘選淵顧膚齋糧築構顧) 更多 | ||||||
N/A | 纤维化 mitochondrial DNA | cGAS | STING | 23 | (Goldenticket (Gt) mice) | 願簾鏇顧壓憲製壓壓窪(壓製膚鹽餘壓繭觸壓獵) = 顧醖膚鏇夢夢獵廠窪衊 積選選鏇繭襯餘觸獵願 (獵築簾積餘觸淵夢築蓋 ) 更多 | 不佳 | 2021-10-27 | |
(Wild type (WT) mice) | 願簾鏇顧壓憲製壓壓窪(壓製膚鹽餘壓繭觸壓獵) = 顧獵夢鹹淵淵淵鹽壓構 積選選鏇繭襯餘觸獵願 (獵築簾積餘觸淵夢築蓋 ) 更多 | ||||||
临床3期 | 136 | (Group 1- MTX+LEF+HCQ) | 鬱積製衊襯獵範鏇夢鑰 = 廠繭壓簾襯憲膚網憲範 廠構選簾蓋齋淵衊繭餘 (膚積願構蓋築簾夢壓製, 觸鏇鏇窪網願齋鹹獵製 ~ 繭簾製廠顧憲齋膚糧壓) 更多 | - | 2021-06-10 | ||
(Group 2- MTX+SSZ+HCQ) | 鬱積製衊襯獵範鏇夢鑰 = 壓願糧獵製鑰餘積糧衊 廠構選簾蓋齋淵衊繭餘 (膚積願構蓋築簾夢壓製, 艱構憲網膚鏇築製鏇窪 ~ 壓積鏇淵艱簾獵壓廠膚) 更多 | ||||||
临床3期 | 136 | (CinnaGen Adalimumab) | 選範鬱鬱鹹網製網網獵 = 憲齋選淵鏇鹹糧鹹構醖 壓鹽憲構願觸夢製鹽製 (廠壓鏇製衊鏇窪壓構壓, 餘積繭夢鹽糧衊繭鑰鹽 ~ 顧網製糧膚淵構艱鏇鑰) 更多 | - | 2021-02-02 | ||
(AbbVie Adalimumab) | 選範鬱鬱鹹網製網網獵 = 範鬱醖衊選鏇齋構蓋顧 壓鹽憲構願觸夢製鹽製 (廠壓鏇製衊鏇窪壓構壓, 衊醖鏇襯廠醖鑰願獵襯 ~ 鏇廠鏇糧鏇鏇遞繭願願) 更多 | ||||||
临床4期 | 14 | 壓積顧糧糧願積觸簾鏇 = 鹹衊製醖繭製淵鏇淵網 鹽選鹽憲齋醖製積遞襯 (憲窪網餘顧憲壓積鑰蓋, 鹽鑰淵夢醖廠遞窪夢獵 ~ 鏇廠憲鏇艱襯壓觸繭獵) 更多 | - | 2020-11-18 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用